Beyond the Solution
The Latest News from the New Frontier of Pharma
Windgap Medical Appoints Max Meehan as Director of Corporate Development and Strategy
Windgap Medical Appoints Max Meehan as Director of Corporate Development and Strategy
Windgap Medical Appoints Jason Durkin as Vice President, SupplyChain
The autoinjector platform company known for its wet-dry drug delivery technology expands the leadership team.
Windgap Medical Appoints Anthony (“Tony”) Watson as Vice President, Regulatory Affairs and Quality
The autoinjector platform company known for its wet-dry drug delivery technology expands the leadership team.
Windgap Medical Appoints Aaron Mann as CEO, Michael Samar as CFO
The autoinjector platform company known for its wet-dry drug delivery technology deepens its leadership bench.
It’s Time to Level Up Lyo – Introducing a Swift Shift in Dual-chamber Autoinjector Technology
Co-Founder Brent Buchine discusses the need for automated, easy-to-use reconstitution devices, especially in lyophilised medications, and introduces Windgap Medical’s technology platforms, which rise to the challenge.
Windgap Medical, Inc. Closes Over $39 Million of Series B-1 Investment, More Than Twenty Percent Over Its Initial Goal
Windgap Medical, Inc., a leading specialty pharmaceutical and drug delivery platform company, announced today that it has successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital.
Windgap Medical and University of Minnesota Twin Cities Receive $3.2 Million NIH Grant to Develop Cyanide Antidote Autoinjector
Under the grant, researchers from the University's Center for Drug Design, College of Pharmacy, and Massachusetts-based pharmaceutical company Windgap Medical are collaborating to design an autoinjector.
Windgap Medical Announces Partnership with ALK-Abelló for its Epinephrine Autoinjector
Windgap Medical, Inc. announced today that it has a strategic partnership with ALK-Abelló, A/S ("ALK") to commercialize the company's epinephrine autoinjector (EAI) for the treatment of anaphylactic shock.
Windgap Medical Announces Strategic Investment from Molex Ventures
Windgap Medical, Inc. announced today that it has finalized a deal to enable a strategic investment from Molex Ventures, LLC, a subsidiary of Koch Industries ("Molex Ventures").
Massachusetts Life Sciences Center Board Approves New Round of Accelerator Program Loans
Announces next round of Life Sciences Accelerator Loan Program